Biotechnology industries
Nymox Pharmaceutical Corporation has formed a strategic partnership with KlinLab Ltd., a Czech clinical laboratory company, to make its AlzheimAlert product available to physicians throughout the Czech Republic for the diagnosis of Alzheimer disease. This agreement marks a significant step forward in the distribution of the AlzheimAlert test, which measures
Biotechnology industries
Genzyme Corp., a prominent biotechnology firm, has announced its intention to acquire pharmaceutical company Bone Care International for $600 million. Additionally, Angiotech Pharmaceuticals has reported positive preliminary safety results from its trial of the Vascular Wrap paclitaxel-eluting mesh. U.S. BioDefense, a Department of Defense contractor, has filed a provisional
Biotechnology industries
Genzyme Corp., a global biotech giant, has reached a deal to acquire Middleton-based Bone Care International in a deal valued at $600 million. The acquisition combines companies selling drugs that treat patients with chronic kidney disease, including those included in the National Kidney Foundation's treatment guidelines. Genzyme agreed
Biotechnology industries
Bionomics Limited, an Australian-based biotechnology company, has taken a significant step in advancing its proprietary cancer drug target, BNO69, by filing further patent applications in key markets, including the United States. Building on recent scientific breakthroughs, BNO69 has emerged as a promising target for inhibiting angiogenesis, a key factor in
Biotechnology industries
Alchemia chairman Mel Bridges announced a major milestone for the company with the decision to proceed with the lead anticancer compound, ACL16907, to human clinical trials. This development marks the first compound discovered using the company's novel drug discovery technology to advance to clinical candidate status. Alchemia CEO
Biotechnology industries
Icoria, Inc. has begun a significant transformation, shifting its focus from agricultural genomics to biomarker-enabled drug discovery. This shift, following the acquisition of certain agricultural genomics assets by Monsanto Company, led to the resignation of three long-serving board members: Robert M. Goodman, PhD, Susan Harlander, PhD, and Michael Summers. As
Biotechnology industries
ID Biomedical Corporation, a Canadian biotechnology company, has achieved a significant milestone in its efforts to bring a new influenza vaccine to the market. The company has completed the enrollment of 1,000 healthy adults for a clinical trial of its Fluviral vaccine, exceeding its original target of 300 subjects.
Biotechnology industries
Cell Genesys, Inc., a biotechnology company, has announced the appointment of Robert J. Dow as senior vice president, medical affairs. Dow brings over 20 years of biopharmaceutical experience, having previously held senior executive positions at companies such as Biolitec Pharma, Ltd., Quantanova, and Scotia Holdings, plc. He holds a BSc
Biotechnology industries
GPC Biotech, AG, a biotech company focusing on developing anticancer drugs, reported financial results for the fourth quarter and fiscal year ended December 31, 2004. The company's revenues decreased 41% to €12.6 million in 2004 compared to €21.6 million in 2003, primarily due to the expiration
Biotechnology industries
Cephalon, Inc. (CEPH) has reported a significant increase in revenue for 2004, with sales reaching $980.4 million, a 43% increase from 2003. The company's three lead products have posted outstanding sales increases, positioning Cephalon for significant growth ahead. The company's chairman and CEO, Frank Baldino
Biotechnology industries
The Toronto Stock Exchange plans to enhance its competitiveness in the global market by targeting Chinese companies looking for capital, according to Richard Nesbitt, its chief executive. The exchange will focus on sectors such as energy, mining, and biotechnology, which are already strong areas for the TSX. This move comes
Biotechnology industries
Millennium Pharmaceuticals, Inc. has announced final results from a phase I clinical trial of MLN2704 in patients with advanced hormone-refractory prostate cancer, showing promising antitumor activity and a favorable safety profile. The trial demonstrated that MLN2704, a deimmunized monoclonal antibody conjugated to the chemotherapeutic agent DM1, produced sustained antitumor activity,
